About JAMA Oncology
Mary L. (Nora) Disis, MD
Vision. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
Mission. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is a Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at the University of Washington (UW), and a Member of the Fred Hutchinson Cancer Research Center. She is the Associate Dean for Translational Science in the UW School of Medicine, Director of the UW Center for Translational Medicine and Women's Health, and Director, UW Institute for Translational Health Sciences. Dr Disis is an expert in breast and ovarian cancer, immunotherapy, and translational research. For a complete listing of the journal's Editors and Editorial Board, see link to Editors and Publishers below.
Journal Publication and Editorial Information. JAMA Oncology is an international peer-reviewed journal that is published online each Thursday and in a print/online issue every month. The acceptance rate is 21%. Time to initial editorial decision is 1 day without review and 35 days with review. All articles are published Online First within a median of 71 days of acceptance. All research articles are made free access online 12 months after publication. All articles are made free access on The JAMA Network Reader on the day of publication. JAMA Oncology also has an open access option for authors of eligible manuscripts. See Instructions for Authors for details. In addition, the journal is made freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program.
ISSN 2374-2437 (Print)
ISSN 2374-2445 (Online)
Back to top
Why Publish in JAMA Oncology?
JAMA Oncology offers unparalleled reach and an author-friendly approach, from manuscript submission through publication. We offer prompt review and decisions and rapid publication, the impact and reach of The JAMA Network, and a focus on you, the author.
Prompt Decisions and Rapid Publication Timelines
- Highly selective peer review and editorial evaluation, with 21% overall acceptance rate; 10% for research articles
- Time to first decision: 1 day without review; 35 days with review
- Online First: all major articles will be published quickly Online First
- Fast publication: complete editing, formatting, and publication within a median of 71 days of acceptance
- Expedited review and publication for important clinical trials and research to be presented at major meetings
Impact and Reach
- 17,500 oncologists reached each week
- Over 480,000 annual visits to JAMA Oncology website; over 900,000 article views and downloads
- Extensive press coverage, with 9,566 media mentions in 2015 in outlets such as The New York Times and Washington Post
- Broad reach through related commentary, author audio interviews, email alerts, Twitter, Facebook, other social media, and Topic Collections
- International authors: 33% of submissions come from outside the United States
- 125,000 registered users of The JAMA Network Reader, an app that integrates content across the entire JAMA Network of journals and is accessible from any device
- Open access for eligible research articles
- Prompt, expert review and consideration from our experienced editors
- Highest standards followed to improve your accepted manuscript’s accuracy, reliability, and readability for both print and online publication
- CME credit available for lead authors who publish in JAMA Oncology
- Opportunity for your work to be augmented with video and audio
- No author fees: no submission, page, color, or publication charges
- Free access: all Original Investigations are freely available on the day of publication on The JAMA Network Reader and 12 months after publication on the journal's website
- Online extras: ability to post supplemental content online and download your article’s tables and figures as PowerPoint slides
- Open access: Authors of eligible research articles may elect to pay for immediate open access on the day of publication
- The JAMA Network advantage: Authors of papers not accepted by JAMA may have their papers automatically referred to JAMA Oncology
For more information, see JAMA Oncology Instructions for Authors. Submit your manuscript at http://manuscripts.jamaonc.com.
Back to top
Updated October 2016